Ahmedabad-based pharma major Cadila Healthcare on Wednesday said it has received a favourable judgement from a US federal court in a patent infringement case in favour of its US subsidiary, Zydus Pharmaceuticals (USA) Inc. This basically paves the way for the company to launch a generic drug to treat ulcerative colitis in the US market.
Zydus, however, did not comment on when it planned to launch the product in the US. It was the first pharmaceutical company to file an abbreviated new drug application (ANDA) for a generic version of Lialda. Shire has reported annual sales of $714 million for